The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland.
Clinical Trial Spotlights for a variety of different cancer topics include:
Clinical Trial—Dr. James Gulley
- An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC)
NCI-08-C-0166
Clinical Trials—Dr. Giuseppe Giaccone
- A Phase II, Open-Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients With Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regime and Failure of Prior Treatment With Erlotinib
NCI-08-C-0086 - Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-Small Cell Lung Cancer: An International Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-Line, Platinum-Based Combination Chemotherapy
NCI-08-C-0083 - Phase II Study of BAY 43-9006 (Sorafenib) With Evaluation of Ras Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer
NCI-05-C-0049
Clinical Trials—Dr. David Schrump
- Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies
NCI-06-C-0014 - Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion in Patients With Malignancies Involving Lungs, Esophagus, or Pleura
NCI-05-C-0010 - Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Patients With Pulmonary and Pleural Malignancies
NCI-02-C-0205
Clinical Trial—Dr. Howard Fine
- A Phase II Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas
NCI-08-C-0101
Clinical Trial—Dr. Teri Kreisl
Clinical Trial—Dr. Claude Sportès
- A Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion
NCI-03-C-0040
To search all clinical trial summaries, click here
To view archived list of Clinical Trial Spotlights, click here
Back to Top
